
Merck cites EnWave’s REV™ Technology as a Faster, Viable Drying Alternative to Vial-Based Lyophilization for Vaccines and Biologics
EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company” https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) announces today that Merck & Co. Inc (“Merck”) published a research paper citing EnWave’s freezeREV® process as a viable manufacturing alternative to vial-based lyophilization for vaccines and biologics. The research article Read More